Passage Bio Inc (PASG NASDAQ) stock market data APIs
$4.6644
-0.02(-0.4%)
as of July 2, 2026
Try our APIs with
free plan!
Passage Bio Inc Financial Data Overview
Price chart is built with
Anychart
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other programs for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is based in Philadelphia, Pennsylvania.
Prev. Close
4.6644
Open
4.6477
High
4.724
Low
4.4769
52 wk Range
3.29-20
Market Cap
15 036 K
Shares Outstanding
3 213 K
EPS
-2.3579
Beta
1.421
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Passage Bio Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Passage Bio Inc data using free add-ons & libraries
Get Passage Bio Inc Fundamental Data
Passage Bio Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -37 553 000
- Earnings Per Share: -11
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-05-19
- EPS/Forecast: -3.058
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Passage Bio Inc News
New
Weekly Buzz: IONS, MRK Get FDA Approvals; ACHV Gets CRL; ADCT Cuts Jobs; TECH Acquired
(RTTNews) - This week, the biotech sector delivered a mix of FDA and EU approvals, strategic reorganizations, layoff, acquisitions, and late-stage clinical readouts across oncology, metabolic disease,...
Remix to go public in reverse merger with once high-flying Passage Bio
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Dive Brief: Remix Therapeutics is going public via a...
Passage Bio And Remix Therapeutics Enter All-Stock Merger Agreement; Stock Down
(RTTNews) - Passage Bio, Inc. (PASG),a genetic medicines company and Remix Therapeutics, Inc., a clinical-stage biotechnology company developing small-molecule therapies, announced that they have ente...
Passage Bio Inc (PASG) Stock: Should You Buy the Dip For 125% Upside?
Passage Bio Inc (NASDAQ:PASG) is one of the best gene therapy stocks to buy in 2026. While the stock is down around 50% year-to-date, analysts see it surging 125% over the next 12 months.Passage Bio I...
Get Passage Bio Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
